Cantor Fitzgerald Initiates Overweight Coverage on Silence Therapeutics, Calls Stock “Materially Undervalued”
The firm initiated Overweight coverage citing strong divesiran Phase 2 potential and 160%+ upside.
Already have an account? Sign in.